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JOAN H. PARKS and FREDRIC L. COE
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The financial effects of kidney stone prevention. Prevention of nephro-
lithiasis (NL) is now medically feasible and widely recommended. How-
ever, diagnosis and treatment of remediable causes of stones requires
testing and drugs that impose a cost; this cost is balanced by the presumed
reductions in stone related events and medical encounters. In order to
assess the balance between these, we have analyzed results from 1092
patients with NL unselected except for having clinical follow-up during
treatment. From this population, we have derived the changes in rates of
new stones, hospitalizations, cystoscopies, and surgical procedures. From
these changes, and assignment of a range of possible dollar costs, we
estimate that medical stone prevention will result in an average saving of
$2,158 $500 (sEM)/patient/year, which is the difference between an
expenditure of $1,068/patient on yearly drugs and testing, and a reduction
of $3,226 per patient in medical costs. Medical prevention of NL seems
justified on a cost saving basis quite apart from its benefits to patients in
terms of reduced morbidity and risk from procedures, obstruction, and
infection.
Medical prevention is widely accepted and recommended for
patients with recurrent nephrolithiasis [1]. Prospective studies,
both controlled and open, have documented an excellent response
of recurrent nephrolithiasis to medical intervention. In particular,
thiazide, allopurinol, and potassium citrate salts, have been effec-
tive in double-blind prospective trials [2—5]. Their use in combi-
nations, along with diet change and laboratory feedback in open
clinic experiences, have shown even greater apparent stone rate
reductions [6, 7]. The rationale for the use of these treatments is
well justified by our present understanding of the biochemical
bases for stone pathogenesis [81. If we consider only the problem
of reducing recurrence, medical treatment is clearly valuable for
patient care.
However, treatment imposes a financial cost, which must be
weighed against the potential benefits of reduced stone formation.
These costs arise from an amalgam of diagnostic tests, follow-up
tests, and drug expense. Against these are the presumed reduced
costs arising from hospitalizations, procedures, and medical visits
associated with stone formation. Our results of stone treatment
outcome for 1092 patients, unselected with regard to type of stone
or cause of stone is presented here. These results suggest that
prevention may reduce costs, as well as the pain and risk from
procedures and stone passage events.
Methods
A total of 1092 patients with documented kidney stones were
evaluated using clinical and laboratory protocols detailed else-
where [6, 91, and treated to reverse established metabolic causes
of stones [10]. To minimize selection bias within our program, we
report on all patients for whom there are treatment follow-up
data, with no other criteria imposed. For each patient, a uniform
set of data were collected using a protocol begun in 1969 [11, 12].
Using their computerized records, from which we have in the
past published extensive descriptions of kidney stone disease [6,
13—22], the important events concerning stones were counted for
each patient. All stone passage or removal episodes were entered
with their closest date. All x-rays were read by us; the stones were
counted in each kidney, and we drew a picture of their locations
[7], so comparisons could be made over the years. Documentation
of kidney abnormalities included scarring, calyceal diverticulae,
medullary sponge kidney, papillary necrosis, or other anatomical
disorders [7, 19]. Dates of stone passage were obtained from
radiographs, hospital and procedure records, and patient recol-
lection. During treatment, all such episodes were documented
from records we received because of our involvement in direct
patient care. Stone analyses were recorded from laboratory
reports themselves.
All procedures, hospitalizations, and stone events were dated to
their closest date using past medical records, patient recollections,
and bills where available. Medications prescribed for stone pre-
vention were kept by start and stop dates. All phone, clinic, and
other contacts were dated and recorded as text. As a constant test
for accuracy, patients were given the latest version of their
complete computerized record and corrections were solicited. All
such were entered, unless clearly incorrect. This procedure en-
sured a high quality of data during the treatment phase; of course,
since we did not take care of the patients prior to treatment, that
aspect of the record relied on old records and radiographs, as well
as patient recollections.
Each of the patients reported here has been evaluated using
uniform clinical and laboratory protocols [8], in a specialized
laboratory designed for this purpose, and has had treatment
assigned depending upon abnormalities as we have described in
standard textbook sources and reviews [10, 23, 24].
Clinical protocol
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For each patient, a small number of events characterized the
stone disease and its seriousness before and during treatment.
These events represented the major cost of the disease in dollars
and loss of normal health and functioning, as well as exposure to
risk from procedures and hospitalizations.
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Stones. New stones were always defined as stones first appearing
on an x-ray, or passage or removal of a stone not present on a
prior x-ray. The interval in years from the first stone to the date of
entry into our program was divided into the total number of new
stones pre-treatment to calculate the pre-treatment stone rate for
each patient. Similarly, the total new stones during treatment
were divided by the total years between entry and our last contact
with each patient, to derive a treatment new stone rate. For
convenience these rates are expressed as stones/1000 patients!
year.
Procedures. For cystoscopies, shock wave stone disruption, open
surgeries, and hospitalizations, the same procedure was followed.
The resulting rates were calculated for each patient in events/I 000
patients/year for the pre-treatment and treatment intervals. Be-
cause surgery is being replaced by ESWL, we added the two to
achieve a sum for each patient in each period, and calculated the
rate for their sum as above.
Metabolic protocol
In this population, each patient collected three 24-hour urine
samples for measurement of all known stone forming constitu-
ents; three blood samples were drawn after 12 hours without food.
In blood and urine calcium, phosphorus, magnesium, creatinine,
urate, sodium, and potassium were measured. In urine, volume,
pH, oxalate, citrate, sulfate and ammonium ion were also mea-
sured, and cystine screening performed using the nitroprusside
reaction [251. For cystinuric patients, urine cystine was measured
by amino acid chromatography [26]. The blood measurements
were needed to exclude causes of stones such as primary hyper-
parathyroidism and sarcoidosis, and complicating factors such as
renal insufficiency, hyponatremia, hyperuricemia or potassium or
magnesium depletion. The urine measurements were those
needed to measure supersaturation with respect to calcium ox-
alate, calcium phosphate, and uric acid [271. Sodium and potas-
sium measurements were important clinically, because high so-
dium excretions increased urine calcium losses, and urine
potassium levels gave an index of potassium repletion or depletion
from potassium citrate salts and diuretics, respectively.
Treatment protocol
The useful treatments for stones include drugs and alterations
of diet as we have reviewed elsewhere [10]. These treatments were
often used together, and dosages adjusted to achieve a lowering of
supersaturations. Briefly, thiazide, allopurinol, and potassium
citrate have been tested in prospective trials for calcium stones
associated with idiopathic hypercalciuria, hyperuricosuria, and
hypocitraturia, respectively [2—51. Potassium citrate was also used
for uric acid and cystine stones, based on open trials and strong
rationale [26, 281. High fluid intake, and reduced oxalate, purine
and sodium diets were always recommended as untested but
common practice based upon good rationale [101.
Enteric hyperoxaluria was treated with cholestyramine, oral
calcium carbonate, potassium citrate, and reduced fat and re-
duced oxalatc diet, as described from the main studies of the
problem [291. No prospective trials have documented efficacy,
though the rationale is good. D Penicillamine and Thiola were
accepted drugs for cystinuria, as was urine volume above 4 liters
per day. Based upon one prospective trial, acetohydroxamic acid
was used in occasional severe and otherwise intractable struvite
stone disease [30]. Finally, parathyroidectomy was the treatment
for primary hyperparathyroidism, diagnosed using usual clinical
criteria [17, 31, 32j.
Ideally, patients returned for a metabolic follow-up at six weeks
of treatment, and yearly (one 24 hr urine and blood each time), so
that medications and diet could be monitored and adjusted where
necessary, to achieve better control of abnormal urine chemis-
tries. Post-parathyroidectomy, patients were also monitored for
some time, because of well described residual hypercalciuria [321.
Calculations
Rates of events. in all cases, we have calculated the mean rates
as the mean of rates for all patients. This differs greatly from rates
calculated simply by dividing the total stones or procedures for the
population by the total patient years for that population, as we
have done in the past [33J. The change in rate for each event was
calculated for each patient as treatment rate — pretreatment rate.
From these individual changes, mean changes in rate were
calculated for each event for the population.
Costs of events
If we let stand for the change in one of these manifestions,
and in particular to the change in rate/year, then
= cCc + eCe + hCh + pCp (Eq. 1)
where Cc is the cost of a cystoscopic procedure, Ce the cost of a
stone passage event, Ch, the cost of a stone related hospitaliza-
tion, and Cp the cost of a ESWL or stone surgery procedure, and
is the corresponding change in rate/year for these four items; t,
therefore, is the change in yearly cost for the aggregate of the
items comparing treatment to pretreatment. Costs were estimated
as follows: Ce = $1000, per stone event, which included emer-
gency room, office visit, x-ray, and other costs, but not time of lost
work; Cc = $500, for the cystoscopy, including medical fee and
procedure costs, such as the OR, anaesthesiology, and drugs,
including antibiotics; Cp = $5000 for open surgery or ESWL,
including physician fee, the procedure itself, and associated costs;
Ch = $4,500 for each hospital admission, including all costs and
medical fees, exclusive of procedure and cystoscopy charges. All
of these costs were assumed in 1996 dollars, for convenience.
Costs of testing and drugs
For the costs of metabolic evaluation, we assumed three
24-hour urine + blood samples, with measurements as above. At
six weeks of treatment, we assumed another such urine, and one
yearly thereafter. For drug treatment, we assumed it began in year
one and had a constant yearly average cost. Given this, testing and
drug costs may he summarized as:
T = Cd*Y + Ct(#i + y - 1) (Eq.2)
where Ct is the cost of a urine blood test panel, Y is the number
of years of treatment, #i is the initial number of tests in year one,
Cd is the cost of drugs per year of treatment, and T is the total of
all testing and drug costs for the period of Y years.
Rearranging, one obtains a convenient form of Eq. 2:
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Table 1. Summary of drugs prescribed for 72 patients starting medical prevention in 1995
Category # Chain #1 $Iyr Total $/pt yr Chain #2 $/yr Total $/ptyr
Chlorthalidone 12.5 mg 16 17.50 280 17.68 282.88
Chlorthalidone 25 mg 14 35 490 35.37 495.18
Chlorthalidonc 50 mg 3 38.65 115.95 39.02 117.06
Hydrochlorothiazide 25 hid 6 39.34 236.04 43.73 262.38
Hydrochlorothiazide 50 hid 1 78.69 78.69 87.45 87.45
K-Lyte 25 mEq bid 3 779.56 2,338.68 713.14 2139.42
K-Lytc 25 mEq tid 1 1169.35 1169.35 1069.71 1069.71
K-Lyte DS bid 1 1325.60 1325.6 1168.00 1168
Klor-con\EF qam 1 115.30 115.3 98.51 98.51
Klor-con\EF 25 bid 3 230.60 691.8 197.03 591.09
Urocit K 10 mEq 4/d 10 366.31 3663.1 375.07 3750.7
Urocit K 10 mEq 6/d 27 549.47 14835.69 562.61 15190.47
Urocit K 10 mEq 9/d 2 824.20 1648.4 843.92 1687.84
Polycitra K 30 mEq hid 3 510.20 1530.6 — 0
Amiloride 5 mg qam 3 176.62 529.86 181.37 544.11
Amiloride 10 mg qam 4 353.25 1413 362.74 1450.96
Allopurinol 100 qam 1 38.65 38.65 49.97 49.97
Allopurinol 100 mg bid 1 77.31 77.31 99.94 99.94
Allopurinol 300 mg qam 2 49.96 99.92 60.92 121.84
Totals for 72 patients 102 30677.94 29207.51
#/1000 pts/yr 2.65 — $426,082 — $423,297
Of the 72 patients given prescriptions, 10 had the drug or dose changed during the year. Seven patients had sodium restriction with number mg/day
specified. Chain retail price were from phone inquiry. The aveage of $424,690/year/1000 patients used for final estimates.
T=Q(#I—1)+Y(Ct+Cd) (Eq.3)
From the charges above and at other laboratories, Ct could be
fixed as the cost of a full 24-hour urine + blood at $400. We
extracted actual drug prescriptions from the 72 patients who
entered our program beginning 1/1/95 through 12/31/95 to achieve
an estimate of actual drug use. From this list (Table 1), and retail
drug prices at two very large chain stores containing a pharmacy,
we estimated drug costs/year. From this value, which averaged
$424,690 for the two chain stores, for 1000 patients/year, a value
for Cd was deduced.
Net cost effects
Finally, the overall, or net cost for evaluation, and treatment,
Tn, can be summarized:
TN=T+YM (Eq.4)
Several costs were deliberately left out as being difficult to
assign, and probably unrelated to the presence or absence of
prevention. The actual visit for prescribing medication, and the
time involved in telephone clarification of treatment, or possible
visits were not considered. This was not unreasonable, as tele-
phone conversations, and medical visits between attacks in active
stone forming patients were also left out. As well, we neglected
follow-up x-rays, as they were clone at least as often during active
stone disease and between attacks as during prevention. Finally,
we did not consider the rare but expensive special evaluations and
treatments for our few cystinuric patients, nor the high costs
associated with their large and frequent stones. We also did not
consider the single expensive surgery for primary hyperparathy-
roidism because it was followed by little or no subsequent need for
medications or treatments. Because these diseases are systemic,
they will always mandate extensive evaluation and treatment
regardless of cost.
Results
Rates of stones and procedures
Using our treatment method, the rate of stones fell. Mean stone
rate (Table 2) fell from 1752 per 1000 patients/year to 382 per
1000 patients/year (P < 0.001). Of the 1085 patients only 188
formed any stones (17.3%). Among these, the stone rate was
2162/1000 patients per year, not different from the pretreatment
stone rate for these people (2108 stones/1000 patient year), or
from the general rate of 1752 stones/1000 patient years. In all,
treatment caused an 83% remission rate over an average treat-
ment period of 5.39 0.17 (sEM) years, and a total of 5904 patient
years of treatment experience (Table 2). One possible artifact of
stone counting with treatment was a failure to have sufficient
contact with patients to ascertain whether stones have formed.
During treatment, we observed 588 stones (Fig. 1) during 6562
contacts (0.089 stones/contact, or 8.9% positive), compared to
10,782 stones during 9742 contacts before treatment (1.107
stones/contacts, or > 100% positive).
As expected from the fall in stone rate, procedure and hospi-
talization rates fell with treatment (Table 2). The rise in ESWL
rates reflected the increasing use of ESWL from about 1985, and
the fall in surgery rates may partially reflect the switch from open
surgery to ESWL. For this reason, their sum for all estimates was
used. We do not yet have enough data from percutaneous and
endoureteroscopic techniques to make comparisons; they are
accumulated with ESWL. The fall in all rates occurred despite a
high rate of patient contact (Fig. 1); in other words, the fall was
not an artifact of an inadequate opportunity to obtain informa-
tion.
changes in cost
Using our equation (Methods) that estimates cost for stone
passage and procedures (Methods), and including the changes in
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Table 2. Rates of stones and procedures, and costs, before and during treatment
rates we observed, the changes in costs (Table 2) were estimated
as $3,226,500 for 1000 patients in a year of treatment. From the
drug costs estimated from the survey (Table 1), and the estab-
lished prices for 24-hour urine measurements (Methods), the
main costs of evaluation and treatment were calculated. Using this
and the gross savings from Table 2, net savings were calculated as
their difference (Table 3). In addition, from the SEM for each
change in rate (Table 2) the 2 SEM interval could be estimated
(Table 3). Using the above calculations, and assuming that costs of
testing and drugs remained fixed, this interval predicted that the
mean savings was likely between $1,162,000 and $3,162,000.
We compared the rates of stones and procedures and hospital-
izations for those people who did relapse and those who did not
relapse. Even without relapse, stones formed before treatment
may pass or require procedures. For the 897 patients who did not
form a new stone while on treatment, the change in cystoscopy
rate was —244 30, ESWL + surgery —311 38 and hospital-
ization —95 35 per 1000 patients/year, and since there were no
new stones the change in stone formation rate was —1691 151
(the pretreatment rate for this subset of the total patients), for a
total savings of $3,721,000. For the 188 patients who did relapse,
the change in stone rate was 54 633, cystoscopy 2 41, ESWL
+ surgery —68 55 and hospitalization —186 95, for a savings
of $54,300/bOO patients/year. In other words, prevention of
relapse clearly is desirable, but will not totally prevent subsequent
expenses and interventions during the otherwise successful treat-
ment period. Presumably, after a long enough interval, pre-
formed stones would exhaust themselves, hut this was not com-
pleted during our study. On the other hand, relapse is costly.
We also calculated the effects of selection against primary
hyperparathyroidism and eystinuria, which are unusual stone
diseases, in being systemic, and having unusual costs. If the 42
primary hyperparathyroidism patients in this series were excluded,
the four key rates are almost unchanged: —1396, —194, —86, and
—286 for stone events, cystoscopies, procedures, and hospitaliza-
tions/I 000 patients/year (compare to Table 2). If the 13 cystinuric
patients were excluded, the rates did not change, because their
number was so small.
Finally, we estimated the effects of assumed changes in our cost
estimates for events and procedures, one by one. If cystoscopy
cost were as low as $400, or as high as $1000, savings vary from
—$2,138 to —$2,258 (values are in thousands of dollars/1000
patients/year); for stone event cost variations from $500 to $1,250
each, net costs changed from $1,468 to —$2,504; for hospital-
ization, $2,000 to $6,000, costs changed from —$1,439 to —$2,591;
for procedures, a change of $4,000 to $10,000 resulted in cost
changes from —$2,069 to $2,609. In other words, the net effects
varied with assumed costs, but the main conclusion of an approx-
imate net saving was unchanged. Put another way, although our
assumed costs have no rigorous basis, wide variations will have
only modest effects, the main effects being the changes in key
stone related event rates.
Discussion
Our experience is clearly subject to bias and error, as it is an
open 'trial' of a method of treatment. Certainly, the nonspecific
stone clinic effect, perhaps some amalgam of better hydration and
diet, reduces stone rate [34]. Possibly the majority of our patients
came to us at a peak of their stone forming tendency, and we
benefitted from observing its natural decay [22, 351, as has been
suggested. Certainly, we had knowledge of patient treatment, and
through a biased reading of their many x-rays we could have
systematically reduced our estimates of new stone rates. Proce-
dures themselves may be undercounted during treatment because
of biases in ourselves and our patients. Finally, our patients, being
referred to a university, may not properly represent the main
stream of patients encountered in practice.
The stone clinic effect may well he valuable in reducing stones;
in other words, we may have been able to achieve similar results
without as much use of medication. In terms of the present study,
this is not a critical issue. Patients who come to a stone clinic need
evaluation if they have formed significant numbers of stones; our
patients, who were forming 1.752 stones per year on average,
would have been classified as recurrent. As well, their stones show
a crescendo (Fig. 1) near to referral, which would usually mandate
evaluation. Therefore, the main stone clinic effect would have
been to reduce medication rates and tests, thereby improving our
margin of cost saving. This same argument applies to the issue of
spontaneous decay of stone frequency. If it were present, and we
had waited, our cost improvements would have been increased by
Disease
complications
Before Rx
# events
During Rx Before Rx During Rx
#11 000 patient year
1,752 382Stones 10,782 588
Patient years 14,484 5,904
Cystoscopies 1,339 138
ESWL 347 127
Surgery 657 102
ESWL + surgery 1,004 229
Hospitalization 1,940 227
Total
Change
247
64
134
198
375
BeforeRx During Rx Change
$11000 patient year
50
66
40
106
90
1381 169 1,752,000
—199 26 123,500
—90 33 990,000
—288 -4- 34 1,687,500
4,453,000
382,000 1,381,000
25,000
530,000
405,000
1,342,000
The interval in years from the first event to the date of entry into our program is divided into the total new events pre-treatment to calculate the
pre-treatment stone rate for each patient. Similarly, the total new events during treatment are divided by the total years between entry and our last
contact with each patient, to derive a treatment new event rate. We express these rates, for convenience, as events/1000 patients/year. Changes are mean
SUM of the changes in rates for all patients; Before and during Rx rates were converted to cost using the following multipliers: $1,000 per stone event;
$500 for cystoscopy; $5,000 per ESWL or Surgery; $4,500 per hospitalization, entered into Equation 1 (Methods). Rates for stones, cystoscopies,
hospitalizations and ESWL + surgery all fell significantly, P < 0.01 for each.
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Cystoscopy
Hospitalizations
ESWL + surgery
Stones
—20 —10 0
Time before and after entry, years
10
Patient contacts
20
Fig. 1. Patient contacts and stone related events before and during treatment. Each point shows one contact (lowest panel), or stone related event (upper
panels); time before entry is shown as negative numbers. Despite large numbers of contacts, stone related events fell in all categories.
reduced drug use and tests. In other words, we cannot from this
study prove the mechanisms of reduced disease, but can exclude
an important influence of the above two mechanisms on our main
conclusion about reduced cost.
Did we, however, in fact document reduced stones and proce-
dures? For this study, we were careful that our computer records
corresponded to our x-ray readings. We have always drawn
pictures of our x-rays [7], and therefore have at least an objective
record of what we have seen. It is possible that we desired a
reduction of stones enough to compromise readings, and there-
fore stone counts, but so large a deviation as shown here, over
years of actual patient care seems unlikely.
Misreading could also have been a risk for malpractice. We
have been medically responsible for the care of these patients, so
misreading with attendant errors in patient care would have been
very much undesired. The x-rays were all read as well by radiol-
ogists, urologists who cared for the patients, and other doctors.
Systematic undercounting by us would have been a source of
clinical disagreement. The same is true for procedures.
During treatment, we routinely received ongoing patient
records from other doctors involved in direct care of the patients.
Patients received their own records in a complete form, so any
errors or omissions in our records could be corrected by them.
Procedure records were usually available to us, and patients who
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Expenditures/bOO patients, from Results: costs of drugs and testing
were entered into Equation 3 (Methods), using 5.39 years (Results) of
treatment and presenting results here per year of treatment. Net savings
was then calculated from Equation 4 (Methods).
Savings/1000 patients per year of Rx are from Table 2.
Net Savings/bOO = Savings — Expenditures.
Range of savings and of Net savings = SEM.
need procedures despite treatment for stones almost always called
this fact to our attention by phone calls or visits, even before we
received the records of the procedure. Referring physicians also
tended to inform us of procedures, in the hope we could do better
in prevention. By contrast, pretreatment stone records often
relied on memory, or fragments of old records, and were often not
completely reliable; this led to relative undercounting pretreat-
ment compared to during treatment. For these reasons, we believe
our rates are substantially correct, and more likely than not to
represent procedures and stones as lower before treatment than
they actually were, because of poor records.
As to our patients, they were indeed selected, and we can
extrapolate our results to the main body of stone patients only
with considerable reservation. Unfortunately, without the infra-
structure of a referral center or a research protocol, the high
density of data collection we have is unlikely to materialize. In
addition, adherence to a protocol for evaluation and treatment is
also unlikely. In other words, the main sources of the data we need
tend to be affected by referral bias. Even so, at least for patients
with the kind of stone and procedure rates depicted here, medical
evaluation and treatment seems likely to reduce overall costs of
care. At the same time, it is likely to remove from the patients a
considerable burden of pain and unpleasant procedures.
Costs of stones and procedures are estimates. Our last good
data, from patient bills, are from 1989 and 1990. At the present
time costs of emergency rooms, hospital stays, cystoscopies and
surgical procedures vary widely and are seemingly negotiable, as
financing for these costs is in flux. The same is true for costs of
testing and drugs. Our calculations (Results) show as modest
sensitivity of overall savings to variation in each over a reasonable
range. Quite possibly, reduced costs of drugs and testing will be
balanced by changes in costs of hospitalizations and procedures.
In any event, our rate changes and equations can be used as at
least a reasonable basis for estimating the financial effects of
kidney stone prevention.
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